New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Deliver 30% Savings, Halve Timelines and Cut Risk for Biotechs

Avance Clinical, the award-winning Australian & North American market-leading CRO for biotechs, will share new research at BIO 2024 from Frost & Sullivan showing that biotechs can save more than 30% in costs, halve start-up times, and cut risk with CROs that have in-house scientific and regulatory affairs.